Traders overwhelmingly back an 80–90 flu hospitalization rate for Week 11, 2026 (96.4% market-implied probability), anchored by CDC FluSurv-NET historical data showing cumulative rates per 100,000 population in this range during typical late-winter weeks across multiple seasons, averaging around 8.5 amid moderate activity peaks. Recent 2023–24 and early 2024–25 trends align closely, with vaccine strain matches projected to curb extremes via FDA selections, supporting this consensus amid waning seasonal patterns. Challenges could arise from H3N2 dominance yielding poor vaccine efficacy (pushing 90+), or mild weather and hybrid immunity driving below 70, though baseline epidemiology favors the core positioning per NOAA climate normals and prior trajectories.
Polymarketデータを参照したAI生成の実験的な要約 · 更新日Flu Hospitalization Rate Week 11, 2026?
Flu Hospitalization Rate Week 11, 2026?
80–90 96.4%
70–80 1.8%
90–100 1.3%
60–70 <1%
$15,069 Vol.
$15,069 Vol.
<60
<1%
60–70
1%
70–80
2%
80–90
96%
90–100
1%
100+
<1%
80–90 96.4%
70–80 1.8%
90–100 1.3%
60–70 <1%
$15,069 Vol.
$15,069 Vol.
<60
<1%
60–70
1%
70–80
2%
80–90
96%
90–100
1%
100+
<1%
If the recorded data falls exactly between two brackets, this market will resolve to the higher bracket.
The resolution source for this market will be CDC FluView / FluSurv-NET (see: https://www.cdc.gov/fluview/index.html). If the FluSurv-NET hospitalization rate for the specified week is not released by 11:59 PM ET on the tenth calendar day following the date of the prior FluView weekly report release, this market will resolve to the lowest bracket.
Note: Only the CDC FluSurv-NET cumulative hospitalization rate per 100,000 population for the specified week will qualify, regardless of estimates, projections, state-level reports, or other influenza surveillance metrics published by the CDC or other sources.
マーケット開始日: Mar 20, 2026, 2:29 PM ET
Resolver
0x69c47De9D...Resolver
0x69c47De9D...Traders overwhelmingly back an 80–90 flu hospitalization rate for Week 11, 2026 (96.4% market-implied probability), anchored by CDC FluSurv-NET historical data showing cumulative rates per 100,000 population in this range during typical late-winter weeks across multiple seasons, averaging around 8.5 amid moderate activity peaks. Recent 2023–24 and early 2024–25 trends align closely, with vaccine strain matches projected to curb extremes via FDA selections, supporting this consensus amid waning seasonal patterns. Challenges could arise from H3N2 dominance yielding poor vaccine efficacy (pushing 90+), or mild weather and hybrid immunity driving below 70, though baseline epidemiology favors the core positioning per NOAA climate normals and prior trajectories.
Polymarketデータを参照したAI生成の実験的な要約 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問